1. Introduction {#sec1-metabolites-06-00001}
===============

With over 15,000 patients on the waiting list for liver donations and approximately 7000 liver transplants conducted annually, 2000 patients die each year \[[@B1-metabolites-06-00001]\] of acute and chronic liver failure. Hepatic macrosteatosis, defined as abnormal lipid accumulation in hepatocytes in the form of large lipid droplets, predisposes to primary non-function following transplantation and is one of the most common causes for a donor organ removal from the donor pool \[[@B2-metabolites-06-00001]\]. Although a fatty liver can function properly within the body, it fails when it is temporarily removed from circulation due to ischemia/reperfusion (I/R) injury. Thus, pathologic analysis is conducted on all donated livers, and if more than 30% of the hepatocytes appear to be macrosteatotic, the liver is generally discarded from the donor pool. If all steatotic livers could be made suitable for transplantation, more than 1000 viable livers could be added to the donor pool annually, resulting in sufficient transplants that could halve the number of patients dying while on the waiting list \[[@B3-metabolites-06-00001]\]. Furthermore, the obesity epidemic is expected to drastically increase the proportion of steatotic livers in the donor pool; thus, it is essential that techniques to recover otherwise discarded fatty livers be developed.

Previous work using pharmacological and surgical preconditioning has shown encouraging results in the attempts to stymie ischemia-reperfusion (I/R) injury on steatotic livers. For example, pharmacological preconditioning with tacrolimus of obese Zucker rat livers marginally increased their viability after liver reperfusion, likely due to increased mitochondrial ATP levels \[[@B4-metabolites-06-00001],[@B5-metabolites-06-00001]\]. Cardiotrophin-1 has been shown to have protective properties against reactive oxygen species produced during ischemia of non-steatotic pig livers \[[@B6-metabolites-06-00001]\]. Surgical ischemic preconditioning, which involves brief clamping of blood vessels followed by reperfusion, prior to removing the organ from the donor has also been shown to be effective in ameliorating I/R injury on non-steatotic human livers \[[@B7-metabolites-06-00001],[@B8-metabolites-06-00001],[@B9-metabolites-06-00001]\]. Nevertheless, at this point, there are no clinically approved procedures to deal with steatotic livers that exceed the commonly accepted criterion of less than 30% macrosteatosis \[[@B1-metabolites-06-00001]\].

The aforementioned approaches were designed to overcome the effects of I/R injury in fatty livers, as opposed to dealing with the excessive fat load, which is a major cause of exacerbated I/R injury in fatty livers. Recent studies suggest that the primary cause of I/R injury in steatotic livers is the abnormally high intracellular lipid content which leads to larger hepatocytes, diminished vasculature, and inferior mitochondrial functioning \[[@B10-metabolites-06-00001],[@B11-metabolites-06-00001],[@B12-metabolites-06-00001]\]. Furthermore, defatting steatotic hepatocytes ameliorates the effects of I/R injury *in vitro,* and defatting could be implemented in whole livers via a perfusion procedure \[[@B10-metabolites-06-00001],[@B11-metabolites-06-00001],[@B12-metabolites-06-00001],[@B13-metabolites-06-00001]\].

To provide a rational basis for further optimization of the defatting methods, we wish to gain a better insight into the defatting processes that are rate-limiting, as well as the interaction that may exist between defatting and other liver cell functions (e.g., urea synthesis). For this purpose, we measured the metabolic fluxes in HepG2 cells that were made fatty during exposure to different defatting conditions. Fluxes were determined from measured extracellular metabolite rates of change, as well as a steady-state metabolic flux analysis (MFA) model to infer strictly intracellular fluxes. No isotopic labeling was used for our MFA, unlike other methods, such as 13C MFA \[[@B14-metabolites-06-00001]\].

2. Results {#sec2-metabolites-06-00001}
==========

HepG2 cells have been previously shown to accurately depict hepatic metabolic function \[[@B15-metabolites-06-00001],[@B16-metabolites-06-00001],[@B17-metabolites-06-00001],[@B18-metabolites-06-00001],[@B19-metabolites-06-00001],[@B20-metabolites-06-00001]\], and were therefore used as a surrogate system to evaluate the effects of steatosis and subsequent defatting on liver metabolism. The cells were grown to confluence, at which point they reach a growth-arrested state, then exposed to fatty acid supplemented medium for 2 days to induce steatosis, after which different defatting conditions were tested ([Figure 1](#metabolites-06-00001-f001){ref-type="fig"}). In total, four cultured conditions were studied: (A) steatotic HepG2 cells exposed to basal medium containing no fatty acids; (B) steatotic HepG2 cells exposed to basal medium containing no fatty acids but supplemented with the defatting cocktail; (C) steatotic HepG2 cells exposed to the defatting cocktail as in group (B) but, in addition, under hyperoxic conditions. The defatting cocktail is identical to that previously reported and described in the literature \[[@B10-metabolites-06-00001],[@B11-metabolites-06-00001],[@B12-metabolites-06-00001]\], and was previously shown to promote *in vitro* steatosis reduction by activating hepatocellular TG metabolism \[[@B21-metabolites-06-00001]\]. The fourth group (D) consisted of lean HepG2 cells that were not made steatotic by keeping them in regular basal medium throughout.

![Experimental timeline for macrosteatotic induction and subsequent defatting. HepG2 cells were plated in basal medium for three days in six-well plates. Then, the HepG2 cells were exposed to the basal medium supplemented with free fatty acids to induce steatosis. Two days later, steatotic HepG2 cells were switched to defatting conditions, during which medium samples were taken daily, and cell extracts were harvested to measure intracellular triglyceride content.](metabolites-06-00001-g001){#metabolites-06-00001-f001}

2.1. Triglyceride Storage {#sec2dot1-metabolites-06-00001}
-------------------------

Lean HepG2s exhibited low levels of intracellular TG, as expected. In comparison, steatotic HepG2s stored about 10 times more TG ([Figure 2](#metabolites-06-00001-f002){ref-type="fig"}). When steatotic HepG2s underwent defatting in basal medium (DMEM), intracellular TG decreased by more than 50% within 24 h with no apparent effect of hyperoxia *vs.* normoxia. Furthermore, there was little to no further decrease in stored TG achieved by extending the defatting period from 24 h to 48 h under these conditions, and TG levels remained significantly higher than the lean HepG2s. In medium supplemented with defatting agents, under normoxic conditions, TG content decreased by 32% after 24 h, and by 73% after 48 h. The decrease was more pronounced under hyperoxic conditions, with a 58% decrease at 24 h, and an 83% decrease at 48 h. TG levels after hyperoxic defatting were statistically significantly lower than that observed after normoxic defatting. Furthermore, the combination of defatting agents and hyperoxia for 48 h is the only one that led to TG levels that were statistically indistinguishable from that in lean cells.

![Effect of defatting condition and duration on remaining triglyceride content in steatotic HepG2s. HepG2s were made steatotic by pre-incubation with free fatty acids for two days. Then, the cells were switched to basal medium with no fatty acids (DMEM), or DMEM + defatting cocktail. In each case, defatting was performed under normoxic (21% O~2~ *v/v*) or hyperoxic (90% O~2~ *v/v*). Lean controls consisted of HepG2 cells that were never made steatotic. Data shown represent the amount of triglyceride normalized to cell number in each well, measured before defatting (pre-defat), after 24 h, and after 48 h of defatting. Values are expressed as averages ± S.E.M. for *n* = 3 replicates. \*\*\*: *p* \< 0.001. NS: not significantly different. Comparisons of defatted *vs.* lean groups: ^\#\#\#^ *p* \< 0.001; ^\#\#^ *p* \< 0.01; ^\#^ *p* \< 0.05; *NS*: not significantly different.](metabolites-06-00001-g002){#metabolites-06-00001-f002}

2.2. Measured Metabolic Fluxes {#sec2dot2-metabolites-06-00001}
------------------------------

The measured metabolic fluxes are listed in [Table 1](#metabolites-06-00001-t001){ref-type="table"}, and the main observations are discussed next. Lean cells exhibited net glucose uptake and lactate release, consistent with a glycolytic metabolic pattern. Concurrently, there was a net release of glycerol and ammonia, as well as a very small release of TG and ketone bodies (beta-hydroxybutyrate and acetoacetate). Amino acid uptake rates were all positive, and together added up to a flux totaling 0.35 µg/10^6^ cells/day, which is small (about one seventh) compared to the magnitude ammonia release rates. Finally, cholesterol ester flux was negligible compared to free cholesterol, and a net uptake of cholesterol from the medium was seen.

metabolites-06-00001-t001_Table 1

###### 

Measured metabolite rates during defatting period (µg/10^6^ cells/day) \*.

  Metabolite                        Reaction Number   Lean Normoxia    DMEM Normoxia    Defat Normoxia   Defat Hyperoxia
  --------------------------------- ----------------- ---------------- ---------------- ---------------- -----------------
  **Glycolysis**                                                                                         
  Glucose uptake                    1                 9.49 ± 1.19      −1.63 ± 0.15     0.53 ± 0.18      0.70 ± 0.32
  Lactate uptake                    8                 −14.90 ± 1.09    −1.28 ± 0.08     2.33 ± 0.33      4.80 ± 1.48
  **Ketone Bodies**                                                                                      
  Acetoacetate release              19                −0.42 ± 0.11     0.91 ± 0.45      3.06 ± 1.11      3.88 ± 1.39
  Beta−hydroxybutyrate release      20                −0.13 ± 0.04     0.75 ± 0.13      2.71 ± 0.61      3.83 ± 1.15
  **Oxidative Phosphorylation**                                                                          
  Oxygen uptake                     21                3.79 ± 1.86      3.79 ± 1.86      3.79 ± 1.86      22.15 ± 7.16
  **Amino Acid Metabolism**                                                                              
  Serine (Ser) uptake               28                0.010 ± 0.001    0.006 ± 0.000    0.004 ± 0.002    0.011 ± 0.002
  Glutamine (Gln) uptake            30                0.125 ± 0.040    0.106 ± 0.014    0.057 ± 0.005    0.082 ± 0.010
  Histidine (His) uptake            31                0.018 ± 0.009    0.020 ± 0.009    0.023 ± 0.002    0.003 ± 0.001
  Aspartic acid (Asp) uptake        32                0.013 ± 0.003    0.005 ± 0.001    0.010 ± 0.004    0.013 ± 0.002
  Glutamic acid (Glu) uptake        33                0.005 ± 0.002    0.001 ± 0.000    0.007 ± 0.002    0.012 ± 0.002
  Glycine (Gly) uptake              34                0.002 ± 0.000    0.008 ± 0.001    0.003 ± 0.001    0.002 ± 0.000
  Ammonia (NH~3~+NH~4~^+^) uptake   36                −2.530 ± 0.091   −2.530 ± 1.081   −2.530 ± 0.987   0.540 ± 0.245
  Arginine (Arg) uptake             37                0.016 ± 0.008    0.064 ± 0.010    0.049 ± 0.022    0.040 ± 0.013
  Threonine (Thr) uptake            38                0.022 ± 0.001    0.016 ± 0.001    0.013 ± 0.001    0.012 ± 0.006
  Alanine (Ala) uptake              39                0.007 ± 0.003    0.005 ± 0.002    0.005 ± 0.000    0.002 ± 0.001
  Proline (Pro) uptake              41                0.010 ± 0.002    0.007 ± 0.003    0.010 ± 0.000    0.009 ± 0.004
  Cysteine (Cys) uptake             42                0.008 ± 0.003    0.007 ± 0.003    0.014 ± 0.007    0.005 ± 0.001
  Tyrosine (Tyr) uptake             43                0.014 ± 0.001    0.011 ± 0.005    0.021 ± 0.007    0.008 ± 0.000
  Valine (Val) uptake               45                0.003 ± 0.001    0.023 ± 0.009    0.018 ± 0.007    0.008 ± 0.003
  Ornithine (Orn) uptake            46                0.001 ± 0.000    0.007 ± 0.000    0.001 ± 0.000    0.004 ± 0.001
  Lysine (Lys) uptake               47                0.028 ± 0.002    0.036 ± 0.016    0.042 ± 0.018    0.039 ± 0.001
  Isoleucine (Ile) uptake           48                0.029 ± 0.014    0.018 ± 0.006    0.018 ± 0.005    0.023 ± 0.001
  Leucine (Leu) uptake              49                0.022 ± 0.008    0.024 ± 0.011    0.009 ± 0.001    0.021 ± 0.005
  Phenylalanine (Phe) uptake        50                0.020 ± 0.002    0.007 ± 0.002    0.009 ± 0.004    0.016 ± 0.001
  **Lipid Metabolism**                                                                                   
  Glycerol uptake                   24                −63.39 ± 2.02    30.32 ± 3.92     27.42 ± 3.71     −23.14 ± 9.40
  Triglyceride (TG) uptake ^\#^     27                −0.75 ± 0.22     −20.10 ± 1.52    −36.35 ± 1.96    −44.27 ± 10.58
  Cholesterol ester uptake          74                0.010 ± 0.002    0.003 ± 0.002    0.005 ± 0.002    0.008 ± 0.002
  Free fatty acid (FFA) uptake      84                0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Cholesterol uptake                90                3.24 ± 0.21      6.72 ± 2.24      3.72 ± 1.59      2.91 ± 1.40

\* All metabolites were measured in the culture medium. A negative value indicates a flux in the direction opposite to that shown in [Figure 6](#metabolites-06-00001-f006){ref-type="fig"}. All values report uptake rates, with the exception of the ketone bodies, which show release rates into the medium; ^\#^ Represents uptake into the intracellular lipid droplet pool.

Comparing lean *vs.* steatotic HepG2 cells, both in DMEM under normoxia, reveals major differences in metabolism. Steatotic HepG2s switched from net uptake to a release in glucose, while lactate release decreased by 10 fold. Glycerol changed from net release to net uptake, concomitant with a net release of ketone bodies. Triglyceride release increased \~25 fold over the lean condition. Amino acid uptake rates added up to 0.37 µg/10^6^ cells/day, and thus were virtually unchanged from that in the lean cells.

Addition of defatting cocktail caused steatotic HepG2 cells to switch from net release of lactate and glucose to net uptake of both metabolites, although the glucose uptake rate was very small (less than one tenth) compared to that observed in lean HepG2s. Furthermore, ketone body secretion was increased \~3 fold. Glycerol uptake did not significantly change, but triglyceride release increased 1.8 fold, while cholesterol uptake decreased \~2 fold, moving towards that originally seen in lean cells. Amino acid uptake rates added up to 0.31 µg/10^6^ cells/day, corresponding to a 20% decrease from what was observed in steatotic HepG2s in DMEM alone with no defatting agents.

Hyperoxic conditions did not impact glucose uptake much, but increased lactate uptake 2 fold, and there was a further increase in ketone body production compared to normoxic conditions. Glycerol switched from net uptake to net release, and triglyceride release increased by an additional 1.2 fold. Ammonia was no longer released and a net uptake was measured. Cholesterol uptake further decreased to a level slightly below that originally seen in lean cells. Amino acid uptake rates added up to 0.31 µg/10^6^ cells/day, which is identical to what was observed in similar, albeit normoxic, conditions.

2.3. Calculated Fluxes {#sec2dot3-metabolites-06-00001}
----------------------

Measured fluxes were inputted into the MFA network model and calculated flux distributions are reported in detail in [Table 2](#metabolites-06-00001-t002){ref-type="table"} and in [Figure 3](#metabolites-06-00001-f003){ref-type="fig"}. Most of the changes were seen in fluxes through the pathways of glycolysis (nos. 1--9), the TCA cycle (nos. 10--14), fatty acid beta oxidation (flux no. 26), and the urea cycle (nos. 52--56).

![Effect of defatting condition on metabolic flux distribution. Numbers on horizontal axis correspond to reaction numbers shown in [Table 2](#metabolites-06-00001-t002){ref-type="table"}. Values shown are calculated using the MFA model with averaged measured fluxes in each group as input. (**A**) Fluxes for steatotic HepG2 cells during defatting under normoxic conditions (21% O~2~ *v/v*) in basal medium (DMEM) *vs.* medium supplemented with defatting agents (Defat). Lean controls are for cells that were never made steatotic; (**B**) Fluxes for steatotic HepG2 cells during defatting in medium supplemented with defatting agents under normoxic (21% O~2~ *v/v*) *vs.* hyperoxic (90% O~2~ *v/v*) conditions. Lean controls are for cells that were never made steatotic.](metabolites-06-00001-g003){#metabolites-06-00001-f003}

metabolites-06-00001-t002_Table 2

###### 

Calculated flux distribution during defatting period (µmol/10^6^ cells/day).\*

  Stoichiometry                                                              Rxn Number   Lean Normoxia    DMEM Normoxia    Defat Normoxia   Defat Hyperoxia
  -------------------------------------------------------------------------- ------------ ---------------- ---------------- ---------------- -----------------
  **Glycolysis**                                                                                                                             
  Glucose + ATP \--\> G-6-P                                                  1            0.010 ± 0.001    −0.002 ± 0.000   0.001 ± 0.000    0.001 ± 0.000
  G-6-P \--\> F-6-P                                                          2            0.013 ± 0.002    0.128 ± 0.009    0.212 ± 0.011    0.242 ± 0.059
  F-6-P + ATP \--\> Glyceraldehyde-3-P + DHAP                                3            0.013 ± 0.002    0.128 ± 0.009    0.212 ± 0.011    0.242 ± 0.059
  DHAP \--\> Glyceraldehyde-3-P                                              4            0.013 ± 0.002    0.128 ± 0.009    0.212 ± 0.011    0.242 ± 0.059
  Glyceraldehyde-3-P \--\> 3-PGA                                             5            −0.036 ± 0.005   0.306 ± 0.021    0.488 ± 0.025    0.505 ± 0.128
  3PGA \--\> PEP + NADH + 2ATP                                               6            −0.036 ± 0.005   0.306 ± 0.021    0.488 ± 0.025    0.505 ± 0.128
  PEP \--\> Pyruvate                                                         7            −0.036 ± 0.005   0.306 ± 0.021    0.488 ± 0.025    0.505 ± 0.128
  Pyruvate + NADH \--\> Lactate                                              8            −0.015 ± 0.001   −0.001 ± 0.000   0.002 ± 0.000    0.005 ± 0.001
  Pyruvate \--\> Acetyl-CoA + NADH +CO2                                      9            −0.021 ± 0.005   0.307 ± 0.021    0.486 ± 0.025    0.500 ± 0.128
  **TCA Cycle**                                                                                                                              
  Acetyl-CoA + OAA \--\> Citrate                                             10           0.033 ± 0.010    0.909 ± 0.066    1.491 ± 0.079    1.709 ± 0.414
  Citrate \--\> alpha-KG + NADPH +CO2                                        11           0.033 ± 0.010    0.909 ± 0.066    1.491 ± 0.079    1.709 ± 0.414
  alpha-KG \--\> Succinyl-CoA + NADH + CO2                                   12           0.034 ± 0.010    0.911 ± 0.066    1.492 ± 0.079    1.710 ± 0.414
  Succinyl-CoA \--\> Fumarate + FADH2 + ATP                                  13           0.034 ± 0.010    0.911 ± 0.066    1.492 ± 0.079    1.710 ± 0.414
  Fumarate \--\> OAA + NADH                                                  14           0.033 ± 0.010    0.909 ± 0.066    1.491 ± 0.079    1.709 ± 0.414
  **Pentose Phosphate Pathway and Glycogen Metabolism**                                                                                      
  (Glucose)~n-1~ + G-6-P \--\> (Glucose)~n~                                  15           −0.004 ± 0.001   −0.129 ± 0.009   −0.212 ± 0.011   −0.241 ± 0.059
  G-6-P \--\> 12 NADPH + 6 CO2                                               16           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Ketone Body Production                                                                                                                     
  2 Acetyl-COA \--\> Acetoacetyl-CoA                                         17           −0.002 ± 0.000   0.001 ± 0.001    0.005 ± 0.001    0.007 ± 0.002
  Acetoacetyl-CoA \--\> Acetoacetate                                         18           −0.001 ± 0.000   0.002 ± 0.001    0.006 ± 0.001    0.008 ± 0.002
  Acetoacetate Out                                                           19           0.000 ± 0.000    0.001 ± 0.000    0.003 ± 0.001    0.004 ± 0.001
  Acetoacetate + NADH \--\> B-OH butyrate                                    20           0.000 ± 0.000    0.001 ± 0.000    0.003 ± 0.001    0.004 ± 0.001
  Oxidative Phosphorylation                                                                                                                  
  Oxygen In                                                                  21           0.004 ± 0.002    0.004 ± 0.002    0.004 ± 0.002    0.022 ± 0.007
  NADH + 0.5 O2 \--\> 2.5 ATP                                                22           0.014 ± 0.019    1.641 ± 0.118    2.686 ± 0.141    3.059 ± 0.738
  FADH2 + 0.5 O2 \--\> 2 ATP                                                 23           0.035 ± 0.010    0.912 ± 0.066    1.493 ± 0.079    1.711 ± 0.414
  Glycerol and Fatty Acid Metabolism                                                                                                         
  Glycerol + ATP \--\> Glycerol-3-P                                          24           −0.063 ± 0.002   0.030 ± 0.004    0.027 ± 0.004    −0.023 ± 0.009
  Glycerol-3-P \--\> Glyceraldehyde-3-P + NADH                               25           −0.063 ± 0.002   0.050 ± 0.004    0.064 ± 0.004    0.021 ± 0.014
  FA-CoA \--\> 8(9) Acetyl-CoA + 14(16) NADH                                 26           0.006 ± 0.001    0.067 ± 0.005    0.113 ± 0.006    0.136 ± 0.032
  FA-CoA + DAG \--\> TG                                                      27           −0.001 ± 0.000   −0.020 ± 0.002   −0.036 ± 0.002   −0.044 ± 0.011
  **Amino Acid Metabolism**                                                                                                                  
  Ser In                                                                     28           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Ser \--\> NH3 + Pyr                                                        29           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Gln In                                                                     30           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  His \--\> Glu + NH4+                                                       31           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Asp In                                                                     32           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Glu In                                                                     33           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Gly In                                                                     34           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Gly \--\> 2 CO2 + NH3 + NADH + THF + ATP                                   35           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  NH4+ In                                                                    36           −0.003 ± 0.000   −0.003 ± 0.001   −0.003 ± 0.001   0.001 ± 0.000
  Arg In                                                                     37           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Thr \--\> Pyr + CO2 + NH4+ + 2 NADH + FADH2                                38           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Ala In                                                                     39           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Glu + Pyr \--\> Ala + aKG                                                  40           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Pro In                                                                     41           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Cys In                                                                     42           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Tyr In                                                                     43           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Tyr + aKG + 2 O2 \--\> Glu + CO2 + Acetoacetate + Fumarate                 44           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Val + aKG \--\> Glu + CO2 + 2NADH + FADH2 + Succ-CoA                       45           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Orn In                                                                     46           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Lys + 2 aKG + NADPH \--\> 2Glu + Acetoacetyl-CoA + 2CO2 + 4 NADH + FADH2   47           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Ile + aKG \--\> Glu + Succ-CoA + Acetyl-CoA + NADH + FADH2                 48           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Leu + aKG \--\> Glu + Acetyl-CoA + Acetoacetate + CO2 + NADH + FADH2       49           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Phe + O2 \--\> Tyr                                                         50           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Glu + Cys + Gly \--\> GSH                                                  51           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  **Urea Cycle**                                                                                                                             
  HCO3- + NH4+ + Orn + 2 ATP \--\> Citrulline                                52           −0.002 ± 0.000   −0.002 ± 0.000   −0.002 ± 0.000   −0.002 ± 0.000
  Citrulline + Asp + ATP \--\> Fumarate + Arginine                           53           −0.002 ± 0.000   −0.002 ± 0.000   −0.002 ± 0.000   −0.002 ± 0.000
  Arginine \--\> Orn + Urea                                                  54           0.023 ± 0.014    1.276 ± 0.092    2.089 ± 0.110    2.366 ± 0.576
  Urea Out                                                                   55           −0.013 ± 0.007   −0.638 ± 0.046   −1.046 ± 0.055   −1.182 ± 0.288
  Orn + alpha-KG + 0.5 NADPH + 0.5 NADH \--\> Pro                            56           0.001 ± 0.000    0.001 ± 0.000    0.001 ± 0.000    0.001 ± 0.000
  **Amino Acid Metabolism (Cont'd)**                                                                                                         
  Gln \--\> Glu + NH4+                                                       57           0.015 ± 0.015    1.267 ± 0.092    2.083 ± 0.110    2.407 ± 0.576
  Asp + NH4+ \--\> Asn                                                       58           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Thr \--\> Pyr + CO2 + NH4+ + 2 NADH + FADH2                                59           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Val + aKG \--\> Glu + CO2 + 2NADH + FADH2 + Succ-CoA                       60           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Lys + 2 aKG + NADPH \--\> 2Glu + Acetoacetyl-CoA + 2CO2 + 4 NADH + FADH2   61           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Ile + aKG \--\> Glu + Succ-CoA + Acetyl-CoA + NADH + FADH2                 62           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Leu + aKG \--\> Glu + HMG-CoA + NADH + FADH2                               63           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Phe + O2 \--\> Tyr                                                         64           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  **Phospholipid, Sphingolipid, and Cholesterol Metabolism**                                                                                 
  Ser + 1 Palm-CoA + 1 FA-CoA + NADPH \--\> Ceramide + CO2 + FADH2           65           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Ceramide + Phosphatidylcholine \--\> Sphingomyelin                         66           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Acetoacetyl-CoA + Acetyl-CoA \--\> HMG-CoA                                 67           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  HMG-CoA + 2 NADPH (+ 3ATP) \--\> IPP                                       68           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  2 IPP \--\> Geranyl-PP                                                     69           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Geranyl-PP + IPP \--\> Farnesyl-PP                                         70           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  2 Farnesyl-PP + 0.5 NADPH + 0.5 NADH \--\> Squalene                        71           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Squalene + O2 + NADPH \--\> Lanosterol                                     72           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Lanosterol + 10.5 NADPH + 4.5 NADH + 10 O2 \--\> Chol + 3 CO2              73           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Cholesterol Ester \--\> Chol + FA-CoA                                      74           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  2 FA-CoA + Glycerol-3-P \--\> Phosphatidate                                75           −0.001 ± 0.000   −0.020 ± 0.002   −0.036 ± 0.002   −0.044 ± 0.011
  Phosphatidate \--\> DAG                                                    76           −0.001 ± 0.000   −0.020 ± 0.002   −0.036 ± 0.002   −0.044 ± 0.011
  Phosphatidate \--\> CDP-DAG                                                77           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  CDP-DAG + Ser \--\> PhosphatidylSerine                                     78           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  PhosphatidylSerine \--\> PhosphatidylEthanolamine + CO2                    79           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  CDP-DAG + G-3-P \--\> PhosphatidylGlycerol                                 80           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  2 PG \--\> Cardiolipin + Glycerol                                          81           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  DAG + CDP-Choline \--\> PhosphatidylCholine                                82           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  DAG + CDP-Ethanolamine \--\> PhosphatidylEthanolamine                      83           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  Cholesterol Out                                                            84           0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000    0.000 ± 0.000
  **Polyamine and NADPH**                                                                                                                    
  Arg \--\> Putrescine + 2 CO2 + 2 NH3                                       85           0.011 ± 0.007    0.637 ± 0.046    1.045 ± 0.055    1.181 ± 0.288
  Arg \--\> Putrescine + CO2 + Urea                                          86           −0.036 ± 0.022   −1.914 ± 0.138   −3.134 ± 0.165   −3.548 ± 0.864
  Putrescine + alpha-KG + O2 \--\> NH3 + NADH + Glu + NADPH + Succinate      87           −0.022 ± 0.015   −1.273 ± 0.092   −2.087 ± 0.110   −2.364 ± 0.576
  Putrescine + 2 alpha-KG \--\> 1.5 NADH + 2 Glu + 0.5 NADPH + Succinate     88           −0.003 ± 0.000   −0.004 ± 0.002   −0.003 ± 0.002   −0.003 ± 0.001
  Glu + 2 NADPH \--\> Pro                                                    89           −0.025 ± 0.015   −1.278 ± 0.092   −2.090 ± 0.110   −2.367 ± 0.576
  FA \--\> FA-CoA                                                            90           0.003 ± 0.000    0.007 ± 0.002    0.004 ± 0.002    0.003 ± 0.001
  8 Acetyl-CoA + 14 NADPH \--\> Palm-CoA                                     91           −0.001 ± 0.000   −0.020 ± 0.002   −0.036 ± 0.002   −0.044 ± 0.011

\* data shown are averages of *n* = 3 experiments ± S.E.M. A negative value indicates flux is in the opposite direction of that shown in [Figure 6](#metabolites-06-00001-f006){ref-type="fig"}.

As shown in [Figure 3](#metabolites-06-00001-f003){ref-type="fig"}A, lean HepG2s generally exhibited low flux values for these pathways. In fatty HepG2s in basal DMEM under a normoxic atmosphere (same conditions as the lean cells), the fluxes were greater for most of the aforementioned reactions. With the fatty HepG2s, addition of the defatting cocktail to basal DMEM increased glycolysis by \~60%, TCA cycle fluxes by 64%, oxidative phosphorylation by 64%, beta oxidation by 69% and urea cycle flux by 64%. As shown in [Figure 3](#metabolites-06-00001-f003){ref-type="fig"}B, switching from normoxic to hyperoxic conditions in the presence of the defatting cocktail had little to no effect on most of the glycolytic pathway (increase of \~3% in pyruvate generation), but increased the other aforementioned fluxes by about 15%.

An integrated view of the major changes is shown in [Figure 4](#metabolites-06-00001-f004){ref-type="fig"}. The extracellular glucose fluxes were generally low and most of the carbon source for glycolysis was derived from glycogen. These fluxes were increased by switching to medium containing defatting cocktail, and even more by adding hyperoxic conditions. TCA cycle fluxes increased in parallel, although to a higher extent in relative terms. The acetyl-CoA fed into the TCA cycle originated from glycolysis via decarboxylation of pyruvate, and from beta-oxidation of free fatty acids (FFA) liberated from TG storage by lipolysis. Thus, the additional TCA cycle flux not accounted for by glycolytic changes could be attributed to breakdown and oxidation of stored TG. Ketone body output increased proportionally; however, the values were minimal suggesting that the bulk of the acetyl-CoA went into the TCA cycle. Urea cycle fluxes paralleled the changes in the TCA cycle, although they did not play a direct role in TG removal.

![Summary of major fluxes during defatting of steatotic HepG2s. Values shown are representative fluxes (reaction number is shown) for each major pathway from [Table 2](#metabolites-06-00001-t002){ref-type="table"} estimated by MFA during defatting under normoxic conditions with basal medium (DMEM), medium supplemented with defatting agents, and under hyperoxic conditions with medium supplemented with defatting agents.](metabolites-06-00001-g004){#metabolites-06-00001-f004}

2.4. Urea Flux Validation {#sec2dot4-metabolites-06-00001}
-------------------------

Urea secretion was measured experimentally but not used as input to the MFA model. Thus, we compared measured *vs.* calculated values to assess the ability of the MFA model to predict fluxes. Values of measured *vs.* calculated urea fluxes for the three defatting conditions (normoxic basal DMEM, normoxic DMEM + defatting cocktail, hyperoxic DMEM+defatting cocktail) are reported in [Figure 5](#metabolites-06-00001-f005){ref-type="fig"}. The data exhibited a linear correlation (R^2^ = 0.89); however, calculated fluxes tended to be approximately one third of the measured values.

![Comparison of measured and calculated urea fluxes. The measured urea secretion rate is plotted against the urea cycle output predicted by MFA using the data set shown in [Table 1](#metabolites-06-00001-t001){ref-type="table"}. Measured values are expressed as averages ± S.E.M. for *n* = 3 replicates. The least-square fit line is shown. R^2^ = 0.89.](metabolites-06-00001-g005){#metabolites-06-00001-f005}

3. Discussion {#sec3-metabolites-06-00001}
=============

In this study, we explored the metabolic flux distribution in HepG2 cells that were made severely steatotic by exposure to high levels of free fatty acids. This *in vitro* model of hepatic steatosis (also known as fatty liver) can be used to screen for agents that decrease fat content in the liver \[[@B10-metabolites-06-00001],[@B11-metabolites-06-00001],[@B12-metabolites-06-00001]\]. Upon switching to regular culture medium (containing no free fatty acid supplement), lipid storage decreased over time, as previously reported in HepG2 cells as well as in adult rat hepatocytes \[[@B11-metabolites-06-00001],[@B22-metabolites-06-00001]\]. Accelerated defatting was achieved by adding a cocktail of defatting agents, as well as shifting the cultures from normoxic to hyperoxic conditions. A recent study suggested that a similar defatting cocktail increased beta oxidation as the main route for lipid clearance \[[@B11-metabolites-06-00001]\]. The MFA findings herein suggest the same, whereby fluxes that generate acetyl-CoA from stored TG increased in proportion with the rate of TG removal ([Figure 4](#metabolites-06-00001-f004){ref-type="fig"}). An unexpected result, however, is that the increased fatty acid oxidation occurred in parallel with an increase in glycolysis. The liver is typically glycolytic when the host is in a fed state, a condition which favors fatty acid synthesis and increased lipid storage. Conversely, fatty acid oxidation in liver takes place when the whole organism is fasting and the liver uses ATP derived from this process as a source of energy to drive glucose synthesis by gluconeogenesis from lactate and other suitable carbon sources, such as amino acids \[[@B23-metabolites-06-00001]\]. Thus, the metabolic state of severely steatotic HepG2 cells observed during defatting, which involves concurrent glycolysis and lipid oxidation, was uniquely different. One would normally associate hepatic beta-oxidation as a response to fasting, with concomitant increases in ketone body and glucose production, but this unusual metabolic state has previously been observed \[[@B11-metabolites-06-00001]\]. Furthermore, the particular combination of agents in the defatting medium does not correspond to a physiologically relevant condition; therefore, it is not surprising that an uncommon flux distribution is observed.

The MFA results suggest that the glycolytic pathway was supplied by a breakdown of glycogen, and this supply increased *vs.* control basal medium when using defatting cocktail, and even further when using hyperoxic conditions together with the defatting cocktail. The availability of glucose via glycogenolysis is likely the reason for the lack of gluconeogenesis in our system; it is possible that gluconeogenesis would be activated once glycogen is depleted. Interestingly, the majority of the glucose 6-phosphate from glycogen did not result in a substantial release of glucose into the extracellular medium (flux no. 1); rather, the substrate was used for glycolysis. Furthermore, the rate of pyruvate conversion into lactate (flux no. 8) was very small compared to the decarboxylation of pyruvate into acetyl-CoA (flux no. 9); thus glycogen was mainly oxidized in the TCA cycle.

The substantial increase in TCA cycle fluxes during defatting, using glycogen (via glucose 6-phosphate) and triglyceride (via liberated free fatty acids), is expected to lead to a vast increase in the production of reducing equivalents, and possibly ATP, depending on the efficiency of mitochondrial oxidative phosphorylation. In a prior study, it was found that ATP levels in hepatocytes were slightly higher when defatting agents and defatting agents + hyperoxia were used \[[@B10-metabolites-06-00001]\]. Free fatty acids have been reported to cause mitochondrial uncoupling, which decreases the amount of ATP generated per molecule of NAD(P)H oxidized (sometimes referred to as the P/O ratio). It is possible that the defatting conditions, by liberating fatty acids in the cell, also decrease the P/O ratio. Recent pre-clinical studies in mice have shown that mitochondrial uncouplers are effective and potentially promising therapeutic compounds to decrease fat content in the liver \[[@B24-metabolites-06-00001]\].

The calculated urea cycle flux, when compared to the measured production of urea ([Figure 5](#metabolites-06-00001-f005){ref-type="fig"}), reveals a reasonably good correlation (R^2^ = 0.89), although the measured urea output was three to four times greater than the predicted urea cycle flux. Our flux calculations also predicted high values for reactions that involve putrescine (fluxes no. 85--87). However, these fluxes were expected to be smaller because putrescine and other polyamines are known to be synthesized in small amounts as these molecules mostly play regulatory roles that remain to be fully elucidated \[[@B25-metabolites-06-00001]\]. It is noteworthy that the nitrogen input via amino acids and ammonia in [Table 1](#metabolites-06-00001-t001){ref-type="table"} minus the measured urea release adds up to a net loss of nitrogen ranging from 1 to 5 µmol nitrogen/10^6^ cells/day. A net release of nitrogen is highly suggestive of endogenous protein degradation in the cells. This potential source of nitrogen was not included in the MFA model because it is challenging to experimentally measure this parameter and it has a minor impact on central carbon metabolism \[[@B26-metabolites-06-00001]\], which is the most relevant to lipid clearance. It is unclear whether increased urea cycle fluxes play a useful role in the defatting process, or are merely a by-product of the increased activity of the TCA cycle and oxidative phosphorylation pathways.

The most complete defatting was obtained when the defatting cocktail, together with hyperoxia, were applied to the steatotic HepG2s for 48 h. The TG levels at that point were similar to the lean cells. Such kinetics are similar to that reported for adult rat hepatocytes \[[@B11-metabolites-06-00001],[@B22-metabolites-06-00001]\], but significantly slower to that obtained in one study on whole steatotic livers perfused *ex vivo* \[[@B21-metabolites-06-00001]\]. In this study, we found that the rates in the mitochondrial oxidative phosphorylation reactions were increased several fold in steatotic HepG2 cells compared to the lean HepG2 cells. Furthermore, defatting rate was increased when switching to hyperoxic conditions; thus, oxygen transport to the cells in the static HepG2 culture system clearly augments defatting performance. It is therefore plausible that flow perfusion, by enhancing oxygen delivery to the cells, increases the defatting rate in perfused livers above and beyond what is observed in the HepG2 cultures.

In conclusion, using MFA, we quantitatively described the effects of defatting agents on central carbon metabolism in steatotic HepG2 cells. MFA suggests that in the absence of exogenous free fatty acids in the culture medium, steatotic HepG2 cells decrease their fat content over time. The defatting occurs primarily via beta-oxidation followed by complete oxidation of the generated acetyl-CoA in the TCA cycle. During this time, glycolysis and glycogenolysis remained highly active and also supplied acetyl-CoA to the TCA cycle. The addition of defatting agents enhanced the same fluxes, which could be further increased by the use of hyperoxic conditions. Taken together, these pathways increase the generation of reducing equivalents that are supplied to mitochondrial oxidative phosphorylation.

4. Materials and Methods {#sec4-metabolites-06-00001}
========================

4.1. Materials {#sec4dot1-metabolites-06-00001}
--------------

HepG2 cells were purchased from the American Type Tissue Culture Collection (ATCC; Manassas, VA, USA). Oleic acid and linoleic acid were from Sigma-Aldrich (St. Louis, MO, USA). Bovine serum albumin (BSA), purified by heat shock fractionation, was from Sigma-Aldrich (cat. number A7906). Dulbecco's modified Eagle's medium (DMEM; with 4.5 g/L D-glucose, L-glutamine, and 110 mg/L sodium pyruvate), penicillin-streptomycin (P/S), phosphate buffered saline (PBS, pH = 7.4), and fetal bovine serum (FBS) were from Thermo Scientific (Grand Island, NY, USA). Tissue culture plates and flasks were purchased from Becton-Dickinson (Franklin Lakes, NJ, USA).

4.2. HepG2 Cell Culture {#sec4dot2-metabolites-06-00001}
-----------------------

The HepG2 cells were cultured in T-12.5 flasks and passaged at 70% confluence, using a basal medium consisting of DMEM supplemented with 10% FBS and 2% P/S, and in a 10% CO2/90% air atmosphere. The cells were then transferred into 6-well plates and grown to confluence for 3 days or more. During this time, culture medium was replaced daily with fresh medium (1 mL/well).

4.3. Steatotic Induction and Removal {#sec4dot3-metabolites-06-00001}
------------------------------------

Confluent HepG2 in 6-well plates were switched to fresh basal medium supplemented with free fatty acids (FFAs; 2 mM oleic acid + 2 mM linoleic acid) and BSA (4% *w/v*, to stabilize the fatty acids in solution), which induces intracellular steatosis, for 2 days. This period is considered to be the steatosis induction period ([Figure 1](#metabolites-06-00001-f001){ref-type="fig"}). Cells were then exposed to defatting conditions, which consisted of fresh basal medium with no supplemental fatty acids, or the same with a mixture of the following: 0.01 mM forskolin, 0.001 mM GW7647, 0.01 mM hypericin, 0.01 mM scoparone, 0.001 mM GW501516 and amino acids, as previously described \[[@B10-metabolites-06-00001],[@B11-metabolites-06-00001],[@B12-metabolites-06-00001]\]. This cocktail was previously shown to promote *in vitro* steatosis reduction by activating hepatocellular TG metabolism \[[@B26-metabolites-06-00001]\]. Furthermore, each medium was tested under normoxic (21% O~2~ *v/v*) and hyperoxic (90% O~2~ *v/v*) atmospheres. This period is considered to be the defatting period.

4.4. Metabolite Measurements and Extracellular Flux Calculations {#sec4dot4-metabolites-06-00001}
----------------------------------------------------------------

Fresh medium, and culture medium supernatants (harvested after 24 and 48 h of defatting time) were assayed for the concentration of the following 28 extracellular metabolites (also listed in [Table 1](#metabolites-06-00001-t001){ref-type="table"}): glucose, lactate, glycerol, amino acids, urea, free fatty acids, free cholesterol, cholesterol ester, acetoacetate, and beta-hydroxybutyrate. Amino acids were measured by high-performance liquid chromatography with a Beckman Coulter HPLC Gold 125 system as described in \[[@B27-metabolites-06-00001]\]. Free fatty acids were measured using a commercial kit (Boehringer Mannheim, Mannheim, Germany) based on a reaction catalyzed by acyl-CoA synthetase. Beta-hydroxybutyrate and acetoacetate were measured with Enzychrom assay kits from Gentaur (New York, NY, USA). Urea was measured based on the chromogenic product generated by reaction with diacetyl monoxime in a commercial kit (Sigma-Aldrich). Glucose was measured using a commercially available kit (Sigma-Aldrich), based on a reaction catalyzed by glucose oxidase. Lactate was measured using a commercial kit (Sigma-Aldrich) based on the conversion to pyruvate catalyzed by lactate oxidase. Free cholesterol and cholesterol ester were quantified based upon the reaction catalyzed by cholesterol oxidase using a commercial kit (Sigma-Aldrich). In addition, intracellular triglyceride levels were measured as the amount of glycerol liberated by lipase during an enzymatic assay (Sigma-Aldrich), as described in \[[@B10-metabolites-06-00001],[@B11-metabolites-06-00001],[@B12-metabolites-06-00001]\].

The change in the total amount of metabolite (concentration × total medium volume) between the fresh medium and the medium supernatant at the end of the defatting period, divided by the defatting time period (2 days) was calculated to yield the measured flux per cell well. That number was then normalized to the number of seeded cells.

4.5. MFA Model Establishment {#sec4dot5-metabolites-06-00001}
----------------------------

HepG2 metabolism was represented by a network of known stoichiometric relationships among intracellular and extracellular metabolites. The pathways included in the network, as well as the numbering used for the flux equations comprising the pathways, are shown in [Figure 6](#metabolites-06-00001-f006){ref-type="fig"} and also listed in [Table 1](#metabolites-06-00001-t001){ref-type="table"}. The pathways included are summarized here (flux numbers in brackets): glycolysis (1--9), the TCA cycle (10--14), pentose-phosphate pathway (PPP) and glycogenolysis (15--16), ketogenesis (17--20), oxidative phosphorylation (21--23), FFA synthesis and oxidation (24--27, 75--76, 90), amino acid metabolism (28--51, 56, 58--64, 89), urea cycle (52--55, 57, 85--88), cholesterol synthesis (67--74, 84), and sphingolipid metabolism (65--66), phospholipid synthesis (77--83). This model was adapted from another published MFA model of fattened HepG2 cells studying free fatty acid toxicity in HepG2 cells \[[@B28-metabolites-06-00001],[@B29-metabolites-06-00001]\], with the following major assumptions: (1)The HepG2 cells are in a glycolytic state, and conversion of pyruvate into oxaloacetate by pyruvate carboxylase is assumed to be zero. All pyruvate from glycolysis is either converted to lactate by lactate dehydrogenase, or to acetyl-CoA by pyruvate dehydrogenase.(2)Glycogen nor PPP fluxes were experimentally measured, and was therefore not possible to independently estimate each separately. Since the model predicts a net generation of glucose 6-phosphate from sources other than glucose, it was assumed that PPP fluxes were negligible (flux no.16) and the source of glucose 6-phosphate was entirely from glycogen (flux no. 15).(3)Because we did not measure protein synthesis or degradation, we assumed that there is no contribution of protein synthesis or degradation to the amino acid fluxes. Previously, it was found that albumin (the main protein product from hepatocytes) accounted for little of central carbon and nitrogen metabolism \[[@B26-metabolites-06-00001]\].(4)Although measurements were collected 24 h and 48 h after the onset of the defatting conditions, clearly defatting was very partial at 24 h. Therefore, we chose to calculate the average fluxes over the entire 48 h time period, and the fluxes reported here reflect a time-averaged value over 48 h.(5)Prior reports suggest that HepG2 cells have impaired lipid secretion \[[@B30-metabolites-06-00001],[@B31-metabolites-06-00001]\]; therefore, the secretion of TG into the extracellular medium was neglected compared to the flux of TG released from the intracellular droplet pool. Note that the intracellular TG, which is sequestered in lipid droplets distinct from other metabolically active compartments of the cell, was measured and handled as an extracellular metabolite as described previously \[[@B29-metabolites-06-00001],[@B32-metabolites-06-00001],[@B33-metabolites-06-00001],[@B34-metabolites-06-00001],[@B35-metabolites-06-00001]\].(6)In the presence of high levels of FFAs, prior literature suggests that fatty acid and lipid synthesis are negligible \[[@B36-metabolites-06-00001],[@B37-metabolites-06-00001]\]. Therefore, fatty acid synthesis was set to zero and all fatty acid metabolism was assumed to proceed through degradation pathways.

![Metabolic flux analysis (MFA) reaction map. The metabolic network of the pathways considered in the MFA is shown. Blue ovals denote metabolites that are intracellular, and red rectangles denote metabolites that are extracellular. Note that triglycerides are considered to be an extracellular species because they are sequestered in lipid droplets that are physically separated from the rest of the cell. Extracellular metabolite concentrations were experimentally measured, converted into fluxes, and used as input for the MFA, with the exception of urea, which was used to compare and independently measured flux to that predicted by the MFA model.](metabolites-06-00001-g006){#metabolites-06-00001-f006}

The system of 91 reactions is listed in [Table 2](#metabolites-06-00001-t002){ref-type="table"}. A steady-state mass balance was written around each intracellular metabolite, and the resulting system of linear equations was solved by a least-squares fit via the Moore-Penrose pseudo-inverse calculation, as previously described \[[@B28-metabolites-06-00001]\]. This method was originally described for perfused livers \[[@B38-metabolites-06-00001]\], and later modified for cultured hepatocytes \[[@B29-metabolites-06-00001],[@B32-metabolites-06-00001],[@B33-metabolites-06-00001],[@B34-metabolites-06-00001],[@B35-metabolites-06-00001]\].

4.6. Statistics {#sec4dot6-metabolites-06-00001}
---------------

Experimental studies were performed in triplicate. Data are reported as average rates of uptake/release for each measured metabolite ± standard error of the mean (S.E.M.). The statistical significance of observed differences was determined using one-way ANOVA followed by Fisher's LSD post-hoc test using KaleidaGraph (Synergy Software, Reading, PA, USA) with values of *p* \< 0.05.
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